Why the study?
Does nesiritide improve hemodynamics and symptoms in patients hospitalized for acute decompensated heart failure?
Does nesiritide improve hemodynamics and symptoms in patients hospitalized for acute decompensated heart failure?
Nesiritide is a valuable therapeutic option that improves hemodynamics and dyspnea in patients with acute decompensated heart failure.
Answers are grounded in this paper and cite their sources.
May support nesiritide for acute decompensated heart failure symptom relief; leaves open need for confirmatory randomized trials.
Nesiritide mimics the actions of endogenous B-type natriuretic peptides. Clinical studies on patients who had acute decompensated heart failure demonstrated rapid-onset dose-related vasodilatory effects. Nesiritide reduces pulmonary capillary wedge pressure and improves dypsnea. These effects compared favorably to standard treatments. It decreases preload and afterload and suppresses the renin-angiotensin-aldosterone axis and the release of norepinephrine. Nesiritide also promotes diuresis and has no proarrhythmic effects. Nesiritide is a valuable therapeutic option in the treatment of patients hospitalized for decompensated heart failure. On-going studies target the examination of its long-term effects on mortality and morbidity and its pharmacoeconomic benefits to the healthcare system.
No takes yet. Share an insight, caveat, or question.
Judy W.M. Cheng (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: